SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Unichem Lab receives final ANDA approval for Alfuzosin Hydrochloride Tablets

29 Jan 2016 Evaluate

Unichem Laboratories has received Final ANDA approval (Tentative Approval was received earlier) from the United States Food and Drug Administration (USFDA) for Alfuzosin Hydrochloride Extended-Release Tablets USP. Alfuzosin Hydrochloride Extended-Release Tablets USP 10mg is therapeutically equivalent to Uroxatral Extended-release Tablets, 10 mg, of Concordia Pharmaceuticals, Inc. (Concordia).

Alfuzosin Hydrochloride Extended-Release Tablets USP is the company's first PARA IV ANDA approval from the USFDA. Alfuzosin MCI is an alpha adrenergic antagonist, indicated for the treatment of signs and symptoms of benign prostatic hyperplasia in adults. The product will be commercialized from the company’s Goa plant. Active Pharmaceutical Ingredient will also be made in house at Pithampur API Plant.  The company now has total of 20 ANDA approvals from USFDA. 

Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.

Unichem Lab Share Price

350.85 4.85 (1.40%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×